The A-TANGO consortium supports World Liver Day on April 19th as we stand for the active fight against acute-on-chronic liver failure (ACLF). Currently, there are barely any treatment options for patients suffering from late-stage cirrhosis, a condition that is responsible for approximately 2.4% of deaths worldwide annually and can have various causes - including bacterial or viral infections, non-alcoholic fatty liver disease (NAFLD), or alcohol abuse. Sadly, up to 40% of patients who come to the hospital with decompensated cirrhosis / ACLF die. A-TANGO strives to increase the survival rate with G-TAK - a novel combinatorial therapy, and to decrease the burden on the national healthcare systems, which is caused by a large percentage of patients who never recover fully and require long-term care.

"It's very important to keep your market access strategy up to date" and start strategic planning early for successful commercialization, following the development of a novel drug or therapy - Louise Perrault, President and CEO at IMAC - International Market Access Consulting (based in Switzerland) during yesterday's insightful Masterclass about reimbursement in healthcare. The online Masterclass "Reimbursement in Healthcare - with relevance to new therapies in cirrhosis and acute-on-chronic liver failure (ACLF)" was open to professionals in liver research, biomedicine, or healthcare, and took place on Wednesday, 27 March 2024 (see slide deck). Thank you, Louise, for this excellent learning opportunity!

Explore the complexity of "The Patient-Doctor Relationship and Informed Consent" in the newest podcast episode of the “Interviews with Experts” series by Frances Hand. Join the conversation with Prof. Thomas Berg and Dr. Cornelius Engelmann as they dive into the significance of a robust doctor-patient relationship. Gain insights into the challenges surrounding informed consent amidst stressful decision-making.

Listen now on 🔗 Spotify!